Absence of deletions but frequent loss of expression of p16(INK4) in human ovarian tumours

S. Marchini, A. M. Codegoni, C. Bonazzi, S. Chiari, M. Broggini

Research output: Contribution to journalArticle

40 Citations (Scopus)

Abstract

The cyclin-dependent kinase inhibitor p16 gene (P16, MTS1, CDKN2) has been shown to be altered by deletion or point mutation in some human tumours and cancer cell lines, suggesting that it works as a tumour suppressor. We analysed p16 gene mutation and p16 protein expression in 42 primary ovarian carcinomas and in five human ovarian cancer cell lines. Polymerase chain reaction (PCR) amplifications of exons 1 and 2 of the gene showed no deletion or gross rearrangement in the p16 gene. The lack of deletion was further demonstrated by Southern blot analysis. Looking for point mutations, we used single-strand confirmation polymorphism (SSCP) analysis and, in half of the tumours, we sequenced both strands of exons 1 and 2. No mutations were detected. In 11 out of 42 patients (26%), however, we detected no protein expression by Western blot analysis, suggesting that decreased expression of p16 rather than deletion of the gene can occur in a significant percentage of human ovarian cancers. In the same experiment CDK4 protein was found homogeneously expressed in all the tumour specimens and in the five cell lines. The lack of expression of p16 was not due to hypermethylation of the gene assessed by digestion of genomic DNAs with a methylation sensitive enzyme, suggesting that other mechanisms, not yet identified, are involved in the decreased expression of the p16 gene in human ovarian tumours.

Original languageEnglish
Pages (from-to)146-149
Number of pages4
JournalBritish Journal of Cancer
Volume76
Issue number2
Publication statusPublished - 1997

Fingerprint

p16 Genes
Neoplasms
Point Mutation
Ovarian Neoplasms
Exons
Cyclin-Dependent Kinase Inhibitor p16
Cell Line
Mutation
Proteins
Sequence Deletion
Gene Deletion
Southern Blotting
Tumor Cell Line
Methylation
Genes
Digestion
Western Blotting
Carcinoma
Polymerase Chain Reaction
DNA

Keywords

  • Cell cycle protein
  • Cyclin-dependent kinase
  • Cyclin-dependent kinase inhibitor
  • Ovarian cancer
  • P16/CDKN2

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Absence of deletions but frequent loss of expression of p16(INK4) in human ovarian tumours. / Marchini, S.; Codegoni, A. M.; Bonazzi, C.; Chiari, S.; Broggini, M.

In: British Journal of Cancer, Vol. 76, No. 2, 1997, p. 146-149.

Research output: Contribution to journalArticle

@article{edb6cc8879444b7ca8866dcdba2183a1,
title = "Absence of deletions but frequent loss of expression of p16(INK4) in human ovarian tumours",
abstract = "The cyclin-dependent kinase inhibitor p16 gene (P16, MTS1, CDKN2) has been shown to be altered by deletion or point mutation in some human tumours and cancer cell lines, suggesting that it works as a tumour suppressor. We analysed p16 gene mutation and p16 protein expression in 42 primary ovarian carcinomas and in five human ovarian cancer cell lines. Polymerase chain reaction (PCR) amplifications of exons 1 and 2 of the gene showed no deletion or gross rearrangement in the p16 gene. The lack of deletion was further demonstrated by Southern blot analysis. Looking for point mutations, we used single-strand confirmation polymorphism (SSCP) analysis and, in half of the tumours, we sequenced both strands of exons 1 and 2. No mutations were detected. In 11 out of 42 patients (26{\%}), however, we detected no protein expression by Western blot analysis, suggesting that decreased expression of p16 rather than deletion of the gene can occur in a significant percentage of human ovarian cancers. In the same experiment CDK4 protein was found homogeneously expressed in all the tumour specimens and in the five cell lines. The lack of expression of p16 was not due to hypermethylation of the gene assessed by digestion of genomic DNAs with a methylation sensitive enzyme, suggesting that other mechanisms, not yet identified, are involved in the decreased expression of the p16 gene in human ovarian tumours.",
keywords = "Cell cycle protein, Cyclin-dependent kinase, Cyclin-dependent kinase inhibitor, Ovarian cancer, P16/CDKN2",
author = "S. Marchini and Codegoni, {A. M.} and C. Bonazzi and S. Chiari and M. Broggini",
year = "1997",
language = "English",
volume = "76",
pages = "146--149",
journal = "British Journal of Cancer",
issn = "0007-0920",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Absence of deletions but frequent loss of expression of p16(INK4) in human ovarian tumours

AU - Marchini, S.

AU - Codegoni, A. M.

AU - Bonazzi, C.

AU - Chiari, S.

AU - Broggini, M.

PY - 1997

Y1 - 1997

N2 - The cyclin-dependent kinase inhibitor p16 gene (P16, MTS1, CDKN2) has been shown to be altered by deletion or point mutation in some human tumours and cancer cell lines, suggesting that it works as a tumour suppressor. We analysed p16 gene mutation and p16 protein expression in 42 primary ovarian carcinomas and in five human ovarian cancer cell lines. Polymerase chain reaction (PCR) amplifications of exons 1 and 2 of the gene showed no deletion or gross rearrangement in the p16 gene. The lack of deletion was further demonstrated by Southern blot analysis. Looking for point mutations, we used single-strand confirmation polymorphism (SSCP) analysis and, in half of the tumours, we sequenced both strands of exons 1 and 2. No mutations were detected. In 11 out of 42 patients (26%), however, we detected no protein expression by Western blot analysis, suggesting that decreased expression of p16 rather than deletion of the gene can occur in a significant percentage of human ovarian cancers. In the same experiment CDK4 protein was found homogeneously expressed in all the tumour specimens and in the five cell lines. The lack of expression of p16 was not due to hypermethylation of the gene assessed by digestion of genomic DNAs with a methylation sensitive enzyme, suggesting that other mechanisms, not yet identified, are involved in the decreased expression of the p16 gene in human ovarian tumours.

AB - The cyclin-dependent kinase inhibitor p16 gene (P16, MTS1, CDKN2) has been shown to be altered by deletion or point mutation in some human tumours and cancer cell lines, suggesting that it works as a tumour suppressor. We analysed p16 gene mutation and p16 protein expression in 42 primary ovarian carcinomas and in five human ovarian cancer cell lines. Polymerase chain reaction (PCR) amplifications of exons 1 and 2 of the gene showed no deletion or gross rearrangement in the p16 gene. The lack of deletion was further demonstrated by Southern blot analysis. Looking for point mutations, we used single-strand confirmation polymorphism (SSCP) analysis and, in half of the tumours, we sequenced both strands of exons 1 and 2. No mutations were detected. In 11 out of 42 patients (26%), however, we detected no protein expression by Western blot analysis, suggesting that decreased expression of p16 rather than deletion of the gene can occur in a significant percentage of human ovarian cancers. In the same experiment CDK4 protein was found homogeneously expressed in all the tumour specimens and in the five cell lines. The lack of expression of p16 was not due to hypermethylation of the gene assessed by digestion of genomic DNAs with a methylation sensitive enzyme, suggesting that other mechanisms, not yet identified, are involved in the decreased expression of the p16 gene in human ovarian tumours.

KW - Cell cycle protein

KW - Cyclin-dependent kinase

KW - Cyclin-dependent kinase inhibitor

KW - Ovarian cancer

KW - P16/CDKN2

UR - http://www.scopus.com/inward/record.url?scp=0030981136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030981136&partnerID=8YFLogxK

M3 - Article

C2 - 9231912

AN - SCOPUS:0030981136

VL - 76

SP - 146

EP - 149

JO - British Journal of Cancer

JF - British Journal of Cancer

SN - 0007-0920

IS - 2

ER -